Alzheimer's Amyloid-Clearing Monoclonal Antibody Drug Lecanemab Shows Positive Results, Poised for FDA Approval

Lecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.